Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide in Mechanically Ventilated COVID-19 ARDS Patients
2020-001329-30Phase 4Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of nitric oxide in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19), sponsored by Massachusetts General Hospital. Primary endpoint: Change in oxygenation. Started Apr 2020; status: terminated.
02
Drugs
nitric oxide
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001329-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001329-30.